Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma

5Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outcomes. In this observational, real-world study, patients received a first-line therapy with pazopanib until discontinuation for disease progression or toxicity, then a second-line with everolimus. Primary endpoints were overall survival (OS) for sequence, progression free survival (PFS) for each agent, and safety. Thirty-one patients were included in the analysis: 73.3% of patients underwent nephrectomy before treatment, 25.8% had at least three comorbidities. At the beginning of therapy, the median age was 68 years, with more than 60% of patients older than 65 years. The median OS for sequence was 26.5 months (95% CI 17.4-nc); median PFS was 10.6 months (95% CI 6.3-12.1) with pazopanib and 5.3 months (95% CI 3.8-6.7) with everolimus. The median persistence in pazopanib therapy was 8.1 months (Interquartile Range IQR 5.3-12.7), with 31% of patients who required dose reduction, while persistence in everolimus was 4.4 months (IQR 3.4-6.5). Sequence was well tolerated with a different profile of adverse events for each agent. These data confirmed that pazopanib was effective, even in reduced dosing, and well tolerated and suggested that everolimus may represent an opportunity to continue a therapy when patients cannot further tolerate angiogenesis inhibitors or develop a resistance.

References Powered by Scopus

Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial

2210Citations
N/AReaders
Get full text

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study

1783Citations
N/AReaders
Get full text

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

1585Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma

9Citations
N/AReaders
Get full text

Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: Efficacy and safety

6Citations
N/AReaders
Get full text

A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rossetti, S., D’Aniello, C., Iovane, G., Scagliarini, S., Laterza, M. M., De Vita, F., … Cavaliere, C. (2017). Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma. Frontiers in Pharmacology, 8(JUL). https://doi.org/10.3389/fphar.2017.00484

Readers' Seniority

Tooltip

Researcher 2

50%

Lecturer / Post doc 1

25%

PhD / Post grad / Masters / Doc 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

43%

Nursing and Health Professions 2

29%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Mathematics 1

14%

Save time finding and organizing research with Mendeley

Sign up for free